Goldman Sachs Raises Price Target on Onyx Pharma (ONXX) after FDA Panel Backs CFZ
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs lifted its price target on Onyx Pharmaceuticals (NASDAQ: ONXX) from $52 to $63 after an FDA panel backed CFZ for use in late-stage blood cancer MM.
This raises their probability of CFZ's approval to 95% from 80%, which they see by July 27.
Goldman said they were surprised by the vote, given the issues raised in the FDA panel documents earlier this week. They said the launch will drive growth (>30%) and a transition to profitability.
Higher costs and sales estimates lead to a fall in 2012 non-GAAP EPS estimate to ($3.52) from ($2.77) and a rise in 2013-2015 estimates to ($2.79)/($1.52)/$1.42 from ($3.18)/($1.92)/$0.95.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $44.58 yesterday.
This raises their probability of CFZ's approval to 95% from 80%, which they see by July 27.
Goldman said they were surprised by the vote, given the issues raised in the FDA panel documents earlier this week. They said the launch will drive growth (>30%) and a transition to profitability.
Higher costs and sales estimates lead to a fall in 2012 non-GAAP EPS estimate to ($3.52) from ($2.77) and a rise in 2013-2015 estimates to ($2.79)/($1.52)/$1.42 from ($3.18)/($1.92)/$0.95.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $44.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
